Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Blood
Maria Paola MartelliBrunangelo Falini

Abstract

Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute myeloid leukemia (AML) because they are common (∼30% AML), stable, and behave as a founder genetic lesion. Oncoprotein targeting can be a successful strategy to treat AML, as proved in acute promyelocytic leukemia by treatment with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO), which degrade the promyelocytic leukemia (PML)-retinoic acid receptor fusion protein. Adjunct of ATRA to chemotherapy was reported to be beneficial for NPM1-mutated AML patients. Leukemic cells with NPM1 mutation also showed sensibility to ATO in vitro. Here, we explore the mechanisms underlying these observations and show that ATO/ATRA induce proteasome-dependent degradation of NPM1 leukemic protein and apoptosis in NPM1-mutated AML cell lines and primary patients' cells. We also show that PML intracellular distribution is altered in NPM1-mutated AML cells and reverted by arsenic through oxidative stress induction. Interestingly, similarly to what was described for PML, oxidative stress also mediates ATO-induced degradation of the NPM1 mutant oncoprotein. Strikingly, NPM1 mutant downregulation by ATO/ATRA was shown to potentiate response to the anthracyclin d...Continue Reading

Associated Clinical Trials

References

Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Nov 7, 1998·Nature Genetics·F QuignonH de Thé
Jun 22, 2002·Toxicology Letters·Michael F Hughes
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Jul 12, 2005·Nature·Silvia GrisendiPier Paolo Pandolfi
Mar 17, 2007·Archives of Biochemistry and Biophysics·Tobias JungTilman Grune
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
May 13, 2008·Nature·Keisuke ItoPier Paolo Pandolfi
May 27, 2009·Current Opinion in Hematology·Richard F Schlenk, Konstanze Döhner
Oct 27, 2009·Leukemia Research·Hoang Thanh ChiYuko Sato
Oct 30, 2010·Blood·Brunangelo FaliniTorsten Haferlach
Jul 5, 2011·Blood Reviews·Brunangelo FaliniMaria Paola Martelli
Dec 14, 2011·Hematology·Hartmut Döhner, Verena I Gaidzik
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Jul 11, 2012·The Journal of Cell Biology·Hugues de ThéValérie Lallemand-Breitenbach
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Mar 19, 2014·The Journal of Cell Biology·Umut SahinValérie Lallemand-Breitenbach
Sep 4, 2014·Asian Pacific Journal of Tropical Biomedicine·Hoang Thanh ChiPhan Thi Xinh

❮ Previous
Next ❯

Citations

Dec 2, 2015·Nature Reviews. Clinical Oncology·Catherine C CoombsRoss L Levine
Feb 2, 2016·Future Oncology·Harinder GillYok-Lam Kwong
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Apr 22, 2015·British Journal of Haematology·Brunangelo FaliniMaria Paola Martelli
May 30, 2015·Blood·Steven Grant
Aug 25, 2016·BMC Molecular Biology·Joseph K BoxDerek J Richard
Nov 18, 2015·Clinical Case Reports·Vincent CamusAspasia Stamatoullas
Nov 4, 2016·Annals of Hematology·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Oct 16, 2016·Cell Death and Differentiation·Christina StoeckleHans-Uwe Simon
May 1, 2017·Experimental Hematology·Noortje van GilsLinda Smit
Apr 5, 2018·Leukemia & Lymphoma·Robert L RednerDaniel E Johnson
Aug 5, 2017·Cellular Microbiology·Anis Rageh Al-MalekiJamuna Vadivelu
Oct 3, 2018·Critical Reviews in Food Science and Nutrition·Xiaoling NiXun Cai
Dec 2, 2017·Nature Reviews. Cancer·Hugues de Thé
Mar 13, 2020·Metallomics : Integrated Biometal Science·Qian Qian WangHua Naranmandura
Feb 6, 2020·British Journal of Pharmacology·Yishan YeFlorent Malard
Jan 12, 2020·Cancer Metastasis Reviews·Shannon E Conneely, Rachel E Rau
Apr 9, 2016·Oncotarget·Adele Di MatteoLuca Federici
Dec 1, 2016·International Journal of Hematologic Oncology·Hayley S MaDonald Small
Jan 24, 2017·Leukemia·E M HeathA D Schimmer
Jan 6, 2018·Journal of Hematology & Oncology·Xue Yang, Jianxiang Wang
Apr 17, 2020·Cancers·Marie-Claude Geoffroy, Hugues de Thé
Dec 7, 2019·Cancers·Orsola di Martino, John S Welch
May 16, 2020·International Journal of Molecular Sciences·Konstantin SchuschelJessica I Hoell
Dec 3, 2016·Blood Cancer Journal·C M CsizmarZ Sachs
Dec 1, 2016·International Journal of Hematologic Oncology·Germana CastelliUgo Testa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.